BMS-833923

Catalog No.S7138 Batch:S713801

Print

Technical Data

Formula

C30H27N5O

Molecular Weight 473.57 CAS No. 1059734-66-5
Solubility (25°C)* In vitro DMSO 95 mg/mL (200.6 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description BMS-833923 (XL139) is an orally bioavailable Smoothened antagonist. Phase 2.
Targets
Smoothened [1]
In vitro BMS-833923 reduces hedgehog pathway activity, decreases cell proliferation and induces apoptosis via the intrinsic pathway in esophageal adenocarcinoma (EAC) cell lines. [2] BMS-833923 dose-dependently affects canonical and prostate hedgehog signature gene transcription in vitro. [3]

Protocol (from reference)

Customer Product Validation

Data from [Data independently produced by , , Neoplasia, 2015, 17(7):538-51.]

Data from [Data independently produced by , , Sci Rep, 2017, 7(1):1899]

Selleck's BMS-833923 has been cited by 7 publications

Establishment and characterization of immortalized sweat gland myoepithelial cells [ Sci Rep, 2022, 12(1):7] PubMed: 34997030
Quantitative longitudinal imaging reveals that inhibiting Hedgehog activity alleviates the hypoxic tumor landscape [ Mol Cancer Res, 2021, molcanres.MCR-21-0257-A.2021] PubMed: 34593607
A novel human colon signet-ring cell carcinoma organoid line: establishment, characterization and application [ Carcinogenesis, 2020, 41(7):993-1004] PubMed: 31740922
Hedgehog Signaling Inhibition by Smoothened Antagonist BMS-833923 Reduces Osteoblast Differentiation and Ectopic Bone Formation of Human Skeletal (Mesenchymal) Stem Cells. [ Stem Cells Int, 2019, 2019:3435901] PubMed: 31871467
Inhibition of Gli leads to antitumor growth and enhancement of cisplatin-induced cytotoxicity in large cell neuroendocrine carcinoma of the lung [Ishiwata T Oncol Rep, 2018, 1148-1154] PubMed: 29328464
Disruption of SHH signaling cascade by SBE attenuates lung cancer progression and sensitizes DDP treatment. [Du J, et al. Sci Rep, 2017, 7(1):1899] PubMed: 28507311
Gli1-Mediated Regulation of Sox2 Facilitates Self-Renewal of Stem-Like Cells and Confers Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer [Bora-Singhal N, et al. Neoplasia, 2015, 17(7):538-51] PubMed: 26297432

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.